Results from a Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Repository Corticotropin Injection for Relapsing-Remitting Multiple Sclerosis
Background: Patients with relapsing-remitting multiple sclerosis (RRMS) may experience acute relapses that are nonresponsive (20-35%) to...
Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry
Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...